JP2005501838A5 - - Google Patents

Download PDF

Info

Publication number
JP2005501838A5
JP2005501838A5 JP2003518521A JP2003518521A JP2005501838A5 JP 2005501838 A5 JP2005501838 A5 JP 2005501838A5 JP 2003518521 A JP2003518521 A JP 2003518521A JP 2003518521 A JP2003518521 A JP 2003518521A JP 2005501838 A5 JP2005501838 A5 JP 2005501838A5
Authority
JP
Japan
Prior art keywords
intensity
indol
methylethyl
fluorophenyl
dihydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003518521A
Other languages
English (en)
Other versions
JP4681808B2 (ja
JP2005501838A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2002/008276 external-priority patent/WO2003013512A2/en
Publication of JP2005501838A publication Critical patent/JP2005501838A/ja
Publication of JP2005501838A5 publication Critical patent/JP2005501838A5/ja
Application granted granted Critical
Publication of JP4681808B2 publication Critical patent/JP4681808B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Claims (8)

  1. 下記d値(Å):
    23.8 (vs), 11.8 (w), 7.8 (vs), 7.6 (vw), 7.4 (vw), 6.4 (vw), 6.1 (vw), 5.90 (w), 5.00 (vw), 4.88 (w), 4.73 (m), 4.56 (w), 4.40 (vw), 4.12 (vw), 4.03 (vw), 3.96 (vw), 3.50 (vw), 3.36 (vw), 2.93 (vw),
    [ここで、(vs)=非常に高強度;(m)=中強度;(w)=低強度;そして(vw)=非常に低強度]で表される特徴的なピークを持つ特徴的な粉末X線回折パターンを示す、(±)−7−(3−(4−フルオロフェニル)−1−(1−メチルエチル)−1H−インドール−2−イル)−3,5−ジヒドロキシ−6−ヘプテン酸一ナトリウム塩の結晶多形。
  2. 下記d値(Å):
    24.6 (vs), 12.5 (w), 8.3 (vs), 7.4 (vw), 6.2 (m), 4.97 (w), 4.85 (vw), 4.52 (vw), 4.40 (vw), 4.14 (vw), 3.96 (vw), 3.41 (vw), 3.10 (vw),
    [ここで、(vs)=非常に高強度;(m)=中強度;(w)=低強度;そして(vw)=非常に低強度]で表される特徴的なピークを持つ特徴的な粉末X線回折パターンを示す、(±)−7−(3−(4−フルオロフェニル)−1−(1−メチルエチル)−1H−インドール−2−イル)−3,5−ジヒドロキシ−6−ヘプテン酸一ナトリウム塩の結晶多形。
  3. 35〜50%の範囲の相対湿度に依存して、24.6〜26.2(vs), 12.5〜13.2(w), 8.3〜8.9(vs)及び6.2〜6.7(m)の範囲[ここで、(vs)=非常に高強度;(m)=中強度;(w)=低強度]の粉末X線回折パターンのd値(Å)で表される特徴的なピークに小さなずれを有し得る、(±)−7−(3−(4−フルオロフェニル)−1−(1−メチルエチル)−1H−インドール−2−イル)−3,5−ジヒドロキシ−6−ヘプテン酸一ナトリウム塩の結晶多形。
  4. 下記d値(Å):
    27.6 (m), 13.9 (vw), 9.2 (m), 8.5 (vw), 8.1 (vw), 7.4 (vw), 6.9 (s), 6.1 (vw), 4.98 (m), 4.77 (m), 4.63 (m), 4.15 (w), 4.03 (w), 3.97 (vw), 3.52 (vw), 3.33 (vw), 3.08 (vw), 2.99 (vw),
    [ここで、(s)=高強度;(m)=中強度;(w)=低強度;そして(vw)=非常に低強度]で表される特徴的なピークを持つ特徴的な粉末X線回折パターンを示す、(±)−7−(3−(4−フルオロフェニル)−1−(1−メチルエチル)−1H−インドール−2−イル)−3,5−ジヒドロキシ−6−ヘプテン酸一ナトリウム塩の結晶多形。
  5. 下記d値(Å):
    29.6 (w), 14.8 (vw), 9.9 (w), 8.6 (vw), 8.3 (vw), 7.4 (s), 6.6 (vw), 6.2 (vw), 5.93 (w), 5.03 (m), 4.94 (m), 4.35 (vw), 4.23 (w), 3.98 (vw), 3.54 (vw), 2.98 (vw),
    [ここで、(s)=高強度;(m)=中強度;(w)=低強度;そして(vw)=非常に低強度]で表される特徴的なピークを持つ特徴的な粉末X線回折パターンを示す、(±)−7−(3−(4−フルオロフェニル)−1−(1−メチルエチル)−1H−インドール−2−イル)−3,5−ジヒドロキシ−6−ヘプテン酸一ナトリウム塩の結晶多形。
  6. フルバスタチンナトリウムを、確定した相対湿度を持つ雰囲気に曝露する、請求項1〜5のいずれか1項記載の結晶多形の製造方法。
  7. 高度に結晶性のフルバスタチンナトリウムA形の製造方法であって、(±)−7−(3−(4−フルオロフェニル)−1−(1−メチルエチル)−1H−インドール−2−イル)−3,5−ジヒドロキシ−6−ヘプテン酸一ナトリウム塩の水性溶液を処理して、化合物を少なくとも最小限沈殿させ、続いてこの懸濁液又は沈殿した化合物を凍結乾燥することを特徴とする方法。
  8. 有効量の請求項1〜5のいずれか1項記載の結晶多形又は高度に結晶性のA形、及び薬学的に許容しうる担体を含む、医薬組成物。
JP2003518521A 2001-08-03 2002-07-25 結晶形 Expired - Fee Related JP4681808B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01810756 2001-08-03
PCT/EP2002/008276 WO2003013512A2 (en) 2001-08-03 2002-07-25 Crystalline forms of fluvastatin sodium

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010165635A Division JP2010265308A (ja) 2001-08-03 2010-07-23 結晶形

Publications (3)

Publication Number Publication Date
JP2005501838A JP2005501838A (ja) 2005-01-20
JP2005501838A5 true JP2005501838A5 (ja) 2006-01-05
JP4681808B2 JP4681808B2 (ja) 2011-05-11

Family

ID=8184071

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003518521A Expired - Fee Related JP4681808B2 (ja) 2001-08-03 2002-07-25 結晶形
JP2010165635A Pending JP2010265308A (ja) 2001-08-03 2010-07-23 結晶形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010165635A Pending JP2010265308A (ja) 2001-08-03 2010-07-23 結晶形

Country Status (16)

Country Link
US (1) US6696479B2 (ja)
EP (1) EP1429757B8 (ja)
JP (2) JP4681808B2 (ja)
KR (1) KR100975782B1 (ja)
CN (2) CN102516150A (ja)
AR (1) AR036205A1 (ja)
AT (1) ATE391502T1 (ja)
AU (1) AU2002333271B2 (ja)
CA (1) CA2454072A1 (ja)
DE (1) DE60226044T2 (ja)
ES (1) ES2304140T3 (ja)
HU (1) HUP0401141A3 (ja)
IL (2) IL159861A0 (ja)
PL (1) PL366905A1 (ja)
RU (1) RU2334738C2 (ja)
WO (1) WO2003013512A2 (ja)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
EP1525189A1 (en) * 2002-07-26 2005-04-27 Ciba Specialty Chemicals Holding Inc. Crystalline polymorphic and amorphous forms of benazepril hydrochloride
WO2004096765A2 (en) * 2003-05-01 2004-11-11 Morepen Laboratories Ltd. A novel crystalline polymorph of fluvastatin sodium and a process for preparing it
US7368581B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Process for the preparation of fluvastatin sodium crystal from XIV
US7368468B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
EP1726583A3 (en) * 2003-06-18 2007-05-09 Teva Pharmaceutical Industries Ltd Fluvastatin sodium crystal form LXXIX, processes for preparing it, compositions containing it and methods of using it.
WO2005037424A1 (en) * 2003-10-06 2005-04-28 Solvias Ag Process for the parallel detection of crystalline forms of molecular solids
US7432380B2 (en) 2003-10-16 2008-10-07 Ciba Specialty Chemicals Corp. Crystalline form of Fluvastatin sodium
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
WO2005080332A1 (en) * 2004-01-14 2005-09-01 Cadila Healthcare Limited Novel form of fluvastatin sodium
US20070173536A1 (en) * 2004-02-06 2007-07-26 Ciba Specialty Chemicals Holding Inc. Crystalline forms of zolmitriptan
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
WO2006021967A1 (en) * 2004-08-26 2006-03-02 Biocon Limited Process for the preparation of fluvastatin sodium form a.
WO2006030304A2 (en) * 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Novel forms of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof
US7795451B2 (en) * 2005-02-11 2010-09-14 Jubilant Organosys Limited Polymorphic forms of fluvastatin sodium and process for preparing the same
WO2006109147A1 (en) * 2005-04-12 2006-10-19 Glenmark Pharmaceuticals Limited Substantially pure amorphous fluvastatin, processes for its preparation and pharmaceutical compositions containing same
WO2007039784A2 (en) * 2005-10-06 2007-04-12 Wockhardt Limited A novel crystalline polymorph of fluvastatin sodium and process for preparing it
US20090082572A1 (en) * 2005-11-14 2009-03-26 Hetero Drugs Limited Process for amorphous esomeprazole
JP2007246522A (ja) * 2006-02-27 2007-09-27 Teva Pharmaceutical Industries Ltd フルバスタチンナトリウムの新規形及びその調製方法
US20110015247A1 (en) * 2008-04-04 2011-01-20 Shodhana Laboratories Limited Novel crystalline form of carvedilol dihydrogen phosphate and related processes
CN101684121B (zh) * 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 培美曲塞二酸的新晶型及其制备方法
JP6115288B2 (ja) * 2012-04-27 2017-04-19 株式会社島津製作所 質量分析におけるピーク検出方法及びそのシステム
TW201806928A (zh) * 2016-07-01 2018-03-01 第一三共股份有限公司 胺基羧酸之酸加成鹽的結晶及其製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
AU570021B2 (en) * 1982-11-22 1988-03-03 Novartis Ag Analogs of mevalolactone
PH23486A (en) * 1982-11-22 1989-08-16 Sanzoz Inc Indole analogs of mevalonolactone,pharmaceutical compositions containing the same and method of use thereof
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6124340A (en) * 1996-06-24 2000-09-26 Astra Aktiebolag Polymorphic compounds
JP2004513112A (ja) * 2000-10-31 2004-04-30 チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド フルバスタチンナトリウムの結晶形

Similar Documents

Publication Publication Date Title
JP2005501838A5 (ja)
RU2004106528A (ru) Кристаллические формы
CA2281049A1 (en) Water-soluble pharmaceutical composition in an ionic complex and the use thereof
WO2004098619A3 (en) Treating cartilage / bone conditions with water-soluble strontium salts
MY133624A (en) Thio-substituted indole acetic acid derivatives for the treatment of respiratory disease
JP2008528542A5 (ja)
EP1330435B1 (en) Crystalline forms of fluvastatin sodium
MX9504034A (es) Formas de administracion medicamentosas que contienen acido tioctico, o sales solidas del acido tioctico de liberacion y biodisponibilidad mejoradas.
JP2010508349A5 (ja)
WO2001083439A3 (fr) NOUVELLE FORME CRISTALLINE η DU SEL DE TERT-BUTYLAMINE DU PERINDOPRIL, SON PROCEDE DE PREPARATION, ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT
CA2564030A1 (en) Salt forms of [r-(r*, r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
AU2002223639A1 (en) Crystalline forms of fluvastatin sodium
WO2003087050A2 (fr) Sel de perindopril et les compositions pharmaceutiques qui le contiennent
RU2003118411A (ru) Кристаллические производные 1-метилкарбапенема
AU2002333271A1 (en) Crystalline forms of fluvastatin sodium
CA2498415A1 (en) Solid formulations comprising an indolinone compound
JP2006518354A5 (ja)
JPH10504557A (ja) イブプロフェンおよびコデイン含有の改良された医薬処方
JP2004532828A5 (ja)
WO2007099552A2 (en) Novel crystalline form of atovastatin hemi-magnesium
JP2003522768A5 (ja)
WO2007020009A1 (en) New crystalline form of perindopril erbumine
HU9600758D0 (en) Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption
WO2005079858A1 (en) Stable, palatable syrup containing ibuprofen and method of its preparation
CA2270004A1 (en) Stable mitoxantrone solutions